

## EXERCISE OF OPTIONS

**PERTH, Australia and SAN DIEGO, Calif.** – PYC Therapeutics (ASX: PYC), submits the following Appendices in relation to the issue of shares upon the exercise of options:

Appendix 3Y – Change of Directors Interest Notice – Dr Rohan Hockings  
Section 708A Notice

Yours sincerely

Kevin Hart  
Company Secretary

## About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize PYC's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines. PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including three preclinical stage programs focused on inherited eye diseases and a preclinical discovery program focused on neurodegenerative diseases. PYC's discovery and laboratory operations are located in Australia, and the Company recently launched an expansion into the U.S. for its preclinical, clinical, regulatory and business development operations. For more information, visit [pyctx.com](http://pyctx.com), or follow us on [LinkedIn](#) and [Twitter](#).

## Forward looking statements

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*

*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

*This ASX announcement was approved and authorised for release by Sahm Nasseri, Director and incoming CEO of PYC in the U.S.*

## CONTACTS:

### INVESTORS

Deborah Elson/Matthew DeYoung  
Argot Partners  
[deborah@argotpartners.com](mailto:deborah@argotpartners.com)  
[matthew@argotpartners.com](mailto:matthew@argotpartners.com)

### MEDIA

Leo Vartorella  
Argot Partners  
[leo@argotpartners.com](mailto:leo@argotpartners.com)

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>PYC THERAPEUTICS LIMITED</b>
<b>ABN</b>	<b>48 098 391 961</b>

We, Phylogica Limited, give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Rohan Hockings</b>
<b>Date of last notice</b>	<b>4 December 2018</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	INDIRECT
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Stjepana Maticevic (spouse)
<b>Date of change</b>	10 June 2021
<b>No. of securities held prior to change</b>	10,000,000
<b>Class</b>	Unlisted options exercise price 3.9 cents, expiring 16 November 2021
<b>Number acquired</b>	10,000,000 Ordinary Shares
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Exercise of options
<b>Number disposed</b>	10,000,000 Unlisted options exercise price 3.9 cents, expiring 16 November 2021
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.039 per Ordinary Share
<b>No. of securities held after change</b>	10,000,000 Ordinary Shares

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.

Company Announcements Office  
Australian Securities Exchange  
4th Floor, 20 Bridge Street  
Sydney NSW 2000

### Notice Given Under Section 708A(5)(E) of The Corporations Act 2001 (Cth)

---

PYC Therapeutics Limited (the '**Company**') issued 10,000,000 fully paid ordinary shares in the Company on 10 June 2021 following the exercise of unlisted options. The unlisted options had an exercise price of \$0.039 each and expiry date of 16 November 2021.

PYC Therapeutics Limited advises that:

1. The above shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Cth) (Corporations Act).
2. This notice is given under section 708A(5)(e) of the Corporations Act.
3. As at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company and section 674 of the Corporations Act.
4. As at the date of this notice, there is no 'excluded information' within the meaning of sections 708A(7) and 708A(8) of the Corporations Act (as if this notice were a notice under paragraph 708A(5)(e) of the Corporations Act).

Yours sincerely

Kevin Hart  
Company Secretary